de MirandaPGoodSSYarchoanRThomasRVBlumMRMyersCE. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther1989; 46: 494–500.
6.
KornhauserDMPettyBGHendrixCWWoodsASNerhoodLJBartlettJG. Probenecid and zidovudine metabolism. Lancet1989; 2: 463–5.
7.
FischlMAParkerCBPettinelliCWulfsohnMHirschMSCollierAC. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med1990; 323: 1009–14.
8.
SimSMBackDJBreckenridgeAM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol1991; 32: 17–21.
9.
Drugs used for systemic mycoses. In: Drug evaluations annual 1991. Milwaukee, WI: American Medical Association, 1991: 1479–92.
10.
Fluconazole for fungal infections. FDA Drug Bull1990; 20: 7–8.
11.
Van den BosscheHWillemsensGCoolsWCornellissenFLauwersWFVan CutsemJM. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother1980; 17: 922–8.
12.
BackDJTjiaJF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol1991; 32: 624–6.
Labeling change to reflect drug interaction between terfenadine and ketoconazole. FDA Med Bull1991; 21: 4.
15.
WatkinsPBHamiltonTAAnnesleyTMEllisCNKolarsJCVoorheesJJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther1990; 48: 120–9.
16.
BlumRAWiltonJHHilligossDMGardnerMJHenryEBHarrisonNJ. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther1991; 49: 420–5.
17.
SchmidtDRiedS. Clinical relevance of calcium antagonists in the treatment of epilepsy. Arzneimittelforschung1989; 39: 156–8.
18.
BrandtLSaevelandHLjungrenBAnderssonKE. Control of epilepsy partialis continuans with intravenous nimodipine. Report of two cases. J Newosurg1988; 69: 949–50.
19.
TartaraAGalimbertiCAManniRPariettiLZuccaCBaaschH. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol1991; 32: 335–40.
20.
LangleyMSSorkinEM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cerebrovascular disease. Drugs1989; 37: 669–99.
21.
PantuckEJHsiaoKCMaggioANakamuraKKuntzmanRConneyAH. Effect of cigarette smoking on phenacetin metabolism. Clin Pharmacol Ther1974; 15: 9–17.
22.
GonzalezFJ. Molecular genetics of the P-450 super-family. Pharmacol Ther1990; 45: 1–38.
23.
OkeyAB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther1990; 45: 241–98.
24.
ShimadaTIwasakiMMartinMWGuengerichFP. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens. Cancer Res1989; 49: 3218–28.
25.
ButlerMAIwasakiMGuengerichFPKadlubarFF. Human cytochrome P-450PA (P-4501A2), the phenacetin-O-deethylase is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A1989; 86: 7696–700.
26.
CampbellMESpielbergSPKalowWA. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther1987; 42: 157–65.
27.
KalowWTangBK. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther1991; 99: 44–8.
28.
LewisRJTragerWFChanKKBreckenridgeAOrmeMRowlandM. Warfarin: Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest1974; 53: 1607–17.
29.
SerlinMJSibeonRGMossmanSBreckenridgeAMWilliamsJRBAtwoodJL. Cimetidine interaction with oral anticoagulants in man. Lancet1979; 2: 317–9.
30.
ChoonaraIACholertonSHaynesBPBreckenridgeAMParkBK. Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol1986; 21: 271–7.
31.
NiopasIToonSRowlandM. Further insight into the stereoselective interaction between warfarin and cimetidine in man. Br J Clin Pharmacol1991; 32: 508–11.
LamYWF. Stereoselectivity: An issue of significant importance in clinical pharmacology. Pharmacotherapy1988; 8: 147–57.
34.
SmithDAChandlerMHHShedlofskySIWedlundPJBlouinRA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. Br J Clin Pharmacol1991; 32: 735–9.
35.
ZhouHHAnthonyLBWoodAJJWilkinsonGR. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol1990; 30: 471–5.
36.
KroemerHKFunck-BrentanoCSilbersteinDJWoodAJJEichelbaumMWoosleyRL. Stereoselective disposition and pharmacological activity of propafenone enantiomers. Circulation1989; 79: 1068–76.
37.
BrodeEMullerHPeltzerOHollmannR. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Methods Find Exp Clin Pharmacol1988; 10: 717–27.
38.
KroemerHKFischerCMeeseCOEichelbaumM. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: In vitro evaluation of mechanism. Mol Pharmacol1991; 40: 135–42.
39.
KroemerHKMikusGKronbachTMeyerUAEichelbaumM. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther1989; 45: 28–33.
40.
MastVFischerCMikusGEichelbaumM. Use of pseudoracemic nitrendipine to elucidate the metabolic steps for stereoselective disposition of nitrendipine enantiomers. Br J Clin Pharmacol1992; 33: 51–9.
